A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs AZD 5153 (Primary) ; Olaparib
- Indications Lymphoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 13 Nov 2018 Planned End Date changed from 25 Oct 2019 to 26 Jul 2019.
- 13 Nov 2018 Planned primary completion date changed from 25 Oct 2019 to 26 Jul 2019.
- 01 Oct 2018 Planned End Date changed from 3 Jan 2019 to 25 Oct 2019.